Ongoing activities

Sortcell Analytica technology is being used in different studies.

Breast cancer – Pilot study

Breast cancer stands as the most frequently diagnosed cancer among women worldwide. In 2020, nearly 2.3 million women received a new diagnosis of breast cancer, accounting for approximately 25% of all cancers in women and roughly 12% of all newly reported cancer cases. The treatment of breast cancer has demonstrated remarkable effectiveness, with survival rates often exceeding 90%, especially when the disease is detected at an early stage.

Sortcell Analytica is presently collaborating with researchers from CIMA (University of Navarra), the Liquid Biopsy Analysis Unit (Oncomet), and Santiago University Clinical Hospital in an effort to establish the superior capabilities of our system compared to currently FDA-approved market competitors, such as CellSearch and Parsortix. This pilot study aims to ascertain whether our technology can yield more favorable results than our competitors in the realm of breast cancer diagnosis and analysis.

Liver cancer – Pilot study

Liver cancer ranks as the sixth most prevalent cancer worldwide. In the year 2020, close to 1 million individuals received a new diagnosis of liver cancer. Regrettably, the 5-year survival rate for liver cancer stands at just 20%. Detecting liver cancer in its early stages is often challenging, given that symptoms tend to manifest only in advanced stages of the disease. Therefore, the introduction of a screening test is poised to play a pivotal role in addressing this issue.

Sortcell Analytica’s system is actively utilized by researchers at CIMA (University of Navarra) and clinicians at CUN (Clinica Universidad de Navarra) in the pursuit of establishing the optimal protocol for liver cancer detection. This pilot study seeks to demonstrate that the characterization of circulating tumor cells (CTCs) can furnish information that is equivalent, if not superior, to that obtained through biopsy of a metastatic site. Such findings are anticipated to lay the foundation for the implementation of novel approaches aimed at detecting early-stage liver cancer, potentially improving outcomes for patients facing this formidable disease.

Publications

For Research Use Only. Not for use in diagnostic procedures.